ZIM
TPST icon

Zacks Investment Management’s Tempest Therapeutics TPST Stock Holding History

Zacks Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-31
Closed -$140K – 659
2017
Q2 		$140K Buy
+31
New +$131K ﹤0.01% 561
2017
Q1 		– Sell
-8
Closed -$36K – 727
2016
Q4 		$36K Buy
+8
New +$99.7K ﹤0.01% 634

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Zacks Investment Management's TPST Position: Q3 2017 in Review

Zacks Investment Management sold out of Tempest Therapeutics (TPST) in Q3 2017, closing a stake of 31 shares — an estimated $140K sold.

Zacks Investment Management first reported a position in TPST in Q4 2016 and held it in 2 quarters. The position peaked at $140K in Q2 2017. 47 funds tracked by Wall St. Rank hold TPST as of Q3 2017.

  • Zacks Investment Management reported no remaining Tempest Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Zacks Investment Management sold 31 Tempest Therapeutics shares in Q3 2017, an estimated $140K.
  • Zacks Investment Management first reported a position in Tempest Therapeutics in Q4 2016 and held it in 2 quarters.
  • Zacks Investment Management's Tempest Therapeutics position peaked at $140K in Q2 2017.
  • 47 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2017.

Based on Zacks Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.